135 related articles for article (PubMed ID: 38287797)
61. Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
Roig B; Rodríguez-Balada M; Samino S; Lam EW; Guaita-Esteruelas S; Gomes AR; Correig X; Borràs J; Yanes O; Gumà J
Sci Rep; 2017 Dec; 7(1):17831. PubMed ID: 29259228
[TBL] [Abstract][Full Text] [Related]
62. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
[TBL] [Abstract][Full Text] [Related]
63. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
[TBL] [Abstract][Full Text] [Related]
64. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
65. Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
Santonocito C; Scapaticci M; Guarino D; Bartolini A; Minucci A; Concolino P; Scambia G; Paris I; Capoluongo E
Breast; 2017 Dec; 36():74-78. PubMed ID: 29020660
[TBL] [Abstract][Full Text] [Related]
66. Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
Van Heetvelde M; Van Bockstal M; Poppe B; Lambein K; Rosseel T; Atanesyan L; Deforce D; Van Den Berghe I; De Leeneer K; Van Dorpe J; Vral A; Claes KBM
Cancer Lett; 2018 Jul; 425():125-133. PubMed ID: 29580810
[TBL] [Abstract][Full Text] [Related]
67. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
68. Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers.
Mori T; Okamoto Y; Mu A; Ide Y; Yoshimura A; Senda N; Inagaki-Kawata Y; Kawashima M; Kitao H; Tokunaga E; Miyoshi Y; Ohsumi S; Tsugawa K; Ohta T; Katagiri T; Ohtsuru S; Koike K; Ogawa S; Toi M; Iwata H; Nakamura S; Matsuo K; Takata M
Cancer Med; 2023 Mar; 12(6):6594-6602. PubMed ID: 36345163
[TBL] [Abstract][Full Text] [Related]
69. Transcriptome Patterns of
Arakelyan A; Melkonyan A; Hakobyan S; Boyarskih U; Simonyan A; Nersisyan L; Nikoghosyan M; Filipenko M; Binder H
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525353
[TBL] [Abstract][Full Text] [Related]
70. Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin.
Ruiz de Garibay G; Gutiérrez-Enríquez S; Garre P; Bonache S; Romero A; Palomo L; Sánchez de Abajo A; Benítez J; Balmaña J; Pérez-Segura P; Díaz-Rubio E; Díez O; Caldés T; de la Hoya M
Breast Cancer Res Treat; 2012 May; 133(1):273-83. PubMed ID: 22434521
[TBL] [Abstract][Full Text] [Related]
71. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
72. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
Brandão RD; Mensaert K; López-Perolio I; Tserpelis D; Xenakis M; Lattimore V; Walker LC; Kvist A; Vega A; Gutiérrez-Enríquez S; Díez O; ; de la Hoya M; Spurdle AB; De Meyer T; Blok MJ
Int J Cancer; 2019 Jul; 145(2):401-414. PubMed ID: 30623411
[TBL] [Abstract][Full Text] [Related]
73. Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline BRCA1 mutation: a case report.
Liu Y; Zhu J; Wei X; Yang D; Li S; Qian X; Li L
J Ovarian Res; 2022 Dec; 15(1):127. PubMed ID: 36463302
[TBL] [Abstract][Full Text] [Related]
74. Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
Appel SJ; Cleiment RJ
J Natl Black Nurses Assoc; 2015 Dec; 26(2):17-26. PubMed ID: 27045154
[TBL] [Abstract][Full Text] [Related]
75. Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition.
Macquere P; Orazio S; Bonnet F; Jones N; Bubien V; Chiron J; Lafon D; Barouk-Simonet E; Tinat J; Venat-Bouvet L; Gesta P; Longy M; Sevenet N
J Hum Genet; 2022 Jun; 67(6):339-345. PubMed ID: 35017683
[TBL] [Abstract][Full Text] [Related]
76. The Importance of Extended Analysis Using Current Molecular Genetic Methods Based on the Example of a Cohort of 228 Patients with Hereditary Breast and Ovarian Cancer Syndrome.
Resch LD; Hotz A; Zimmer AD; Komlosi K; Singh N; Tzschach A; Windfuhr-Blum M; Juhasz-Boess I; Erbes T; Fischer J; Alter S
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680878
[TBL] [Abstract][Full Text] [Related]
77. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract][Full Text] [Related]
78. Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.
Pinheiro M; Peixoto A; Santos C; Escudeiro C; Bizarro S; Pinto P; Santos R; Pinto C; Guerra J; Silva J; Teixeira MR
Cancer Genet; 2020 Oct; 248-249():18-24. PubMed ID: 32971473
[TBL] [Abstract][Full Text] [Related]
79. Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
Hoang LN; Gilks BC
Adv Anat Pathol; 2018 Mar; 25(2):85-95. PubMed ID: 28914618
[TBL] [Abstract][Full Text] [Related]
80. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
